# Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

> **NCT07034859** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **National Taiwan University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pituitary Adenoma
- MRI
- RCT

## Interventions

- **DRUG:** Cabergoline 0.5 MG

## Key facts

- **NCT ID:** NCT07034859
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-05-20
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07034859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07034859, "Cabergoline in the Management of Nonfunctioning Pituitary Adenoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07034859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*